Clinical Safety and Effectiveness of Collagenase Clostridium Histolyticum Injection in Patients with Peyronie’s Disease: A Phase 3 Open-Label Study

Collagenase clostridium histolyticum (CCH; Xiaflex, Auxilium Pharmaceuticals, Inc., Chesterbrook, PA, USA) is a Food and Drug Administration-approved, intralesional treatment for Peyronie's disease (PD).The aim of this study was to assess the safety and effectiveness of CCH in the treatment of PD.This phase 3, open-label study enrolled subjects who were CCH-naïve, were enrolled in a previous pharmacokinetic study, or had received placebo in an...